Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, has  acquired Baxter Healthcare Corporation's Enlon product line, including: Enlon (edrophonium chloride injection, USP)

Bioniche purchased the rights and certain assets related to the Enlon product line from Baxter, which discontinued Enlon in February 2008. Bioniche anticipates launching all three codes of Enlon in October 2008.

Enlon is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.Enlon (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial; Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection 5 mL ampule; Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection, 15 mL multi-dose vial.

According to IMS data, 2007 sales of Enlon and Enlon-Plus totalled $2,727,000 and 307,000 units. Enlon-Plus (edrophonium chloride, USP and atropine sulfate, USP) injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage.